Intended for healthcare professionals

Commercial influence in health: from transparency to independence

Growing evidence shows that extensive financial relationships between industry and healthcare decision makers distort scientific research, medical education and the practice of medicine. The biggest problem is that industry sponsored studies produce more favourable results creating biased evidence that overplays benefits and downplays harms. In response, many individuals and groups around the world are moving towards independence from commercial interests in research, education, practice and policy. This BMJ collection charts and encourages that move.

This BMJ collection contains original research and analysis about the impacts of financial conflicts of interest across research, education, practice and policy, and about the global moves to freedom from commercial influence. The aim of the collection is to encourage the production and use of more trustworthy evidence, and tackle the current epidemic of medical excess. As part of the collection, The BMJ invites you to support these moves to independence, offer suggestions for strategies, and express your interest in being involved in the development of more detailed recommendations for change.

Our call for submissions remains open until February 2020 and The BMJ will remain interested in following this theme beyond this date.

Ray Moynihan, Helen Macdonald, Lisa Bero & Fiona Godlee

Please sign our call to action - your opportunity to support greater independence from commercial interests in healthcare and share your thoughts and ideas about how this can be achieved. Read more about the call to action here.

Editorials

Commercial interests, transparency, and independence: a call for submissions
Ray Moynihan, Helen Macdonald, Carl Heneghan, Lisa Bero & Fiona Godlee

Declaring interests and restoring trust in medicine
Carl Heneghan & Margaret McCartney

Analysis

Pathways to Independence: towards producing and using trustworthy evidence
Ray Moynihan, Per Vandvik, Beate Wieseler, et al.

Research

“Asset exchange”—interactions between patient groups and pharmaceutical industry
Lisa Parker, Alice Fabbri, Quinn Grundy, Barbara Mintzes & Lisa Bero

Effect of revealing authors’ conflicts of interests in peer review: randomized controlled trial
Leslie John, George Loewenstein, Andrew Marder & Michael Callaham

Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases
Bruno Goupil, Frédéric Balusson, Florian Naudet, et al.

Opinion

I’m more susceptible to drug company money that I’d like to be
Lisa Parker

Cochrane announces a new, more rigorous “conflict of interest” policy
Karla Soares-Weiser

The sun is shining on the South: advocacy and regulation of conflicts of interest in Chile
Bernardo Aguilera, Juan Carlos Almonte & Rodrigo Irarrázaval

Can expert bias be reduced in medical guidelines?
Sheldon Greenfield

This week's poll